Clinical Trials for Colon Cancer

A Phase I/II Trial of Cabozantinib in Combination with Durvalumab (MEDI4736) with or Without Tremelimumab in Patients with Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and advanced/unresectable gastric/GEJ or esophageal adenocarcinoma (post ≥1 line), colorectal adenocarcinoma (post ≥2 lines; anti-EGFR if RAS WT), or hepatocellular carcinoma (treatment‑naive or previously treated) receive cabozantinib (MET/VEGFR2/AXL multikinase inhibitor) plus durvalumab (PD‑L1 inhibitor), with an HCC cohort also getting a single priming dose of tremelimumab (CTLA‑4 antibody). Baseline/on‑treatment biopsies required; prior PD‑1/PD‑L1 generally excluded except per HCC and gastric/esophageal protocol allowances.

ClinicalTrials.gov ID: NCT03539822

A Phase I/Ib Trial of ProAgio, an Anti-avb3 Integrin Cytotoxin, in Combination With 5-fluorouracil , Irinotecan and Bevacizumab for Advanced/Metastatic Colorectal Cancer (ProAgio in CRC)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced or metastatic colorectal adenocarcinoma and ECOG 0–1 receive investigational ProAgio, an integrin αvβ3–targeting cytotoxin, with FOLFIRI and bevacizumab. Prior FOLFOX for metastatic disease is allowed during dose escalation, but expansion patients cannot have received 5-FU–based therapy for metastatic disease; prior FOLFIRI is excluded.

ClinicalTrials.gov ID: NCT06867822

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR) T Cell Therapy for the Treatment of Relapsed or Refractory Gastrointestinal Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed or refractory, locally advanced or metastatic gastric or colorectal adenocarcinoma, or specified well-differentiated midgut or hindgut neuroendocrine tumors, may be eligible after at least one systemic regimen; gastric tumors must be CDH17-positive. Treatment consists of fludarabine/cyclophosphamide lymphodepletion followed by a single infusion of autologous CDH17-directed CAR T cells.

ClinicalTrials.gov ID: NCT06055439

A Multi-Center, Open Label, Phase 1/2 Study of CP-383, in Patients With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with incurable locally advanced, recurrent, or metastatic solid tumors who lack appropriate standard treatment receive once-daily oral CP-383, an investigational dual DHODH/TEAD4 inhibitor. Dose expansion focuses on selected cancers, including colorectal, small-cell lung, and head and neck cancers, with some cohorts defined by tumor alterations.

ClinicalTrials.gov ID: NCT07030257

A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced solid tumors that have progressed after standard therapy or lack a standard treatment option receive a single intravenous infusion of IDOV-Immune. This engineered oncolytic vaccinia virus is designed to replicate preferentially in tumor cells, destroy them, and stimulate antitumor immunity.

ClinicalTrials.gov ID: NCT06910657

A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, locally advanced unresectable or metastatic FAP-positive solid tumors receive intravenous LY4337713, an investigational lutetium-177 radioligand that targets fibroblast activation protein on cancer-associated fibroblasts to deliver radiation to tumors. Eligible cancers include pancreatic, breast, ovarian, gastric, colorectal, esophageal, and cholangiocarcinoma.

ClinicalTrials.gov ID: NCT07213791

A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with progressing advanced or metastatic CLDN1-positive colorectal, intrahepatic cholangiocarcinoma, squamous non-small cell lung, urothelial, or cervical squamous cancers after standard systemic therapy receive intravenous ALE.P03 monotherapy. ALE.P03 is an investigational CLDN1-targeted antibody–drug conjugate that delivers exatecan, a topoisomerase I inhibitor, to CLDN1-expressing cells.

ClinicalTrials.gov ID: NCT07169734

First-in-Human, Phase 1 Study of PHN-012, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with previously treated, progressive advanced or metastatic colorectal adenocarcinoma, non-small cell lung cancer, or pancreatic ductal adenocarcinoma who have no tolerable standard treatment options receive intravenous PHN-012, an investigational antibody–drug conjugate. Its target antigen and payload have not been disclosed.

ClinicalTrials.gov ID: NCT07127874

First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, advanced CA19-9–expressing solid tumors and no standard treatment option likely to benefit them receive BNT329, an investigational CA19-9–directed antibody–drug conjugate carrying a topoisomerase I inhibitor. Cohorts test different dosing schedules, one with a CA19-9–targeting antibody given before BNT329; a previously treated pancreatic cancer cohort compares two BNT329 doses.

ClinicalTrials.gov ID: NCT07186842

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-08032562 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced or metastatic breast or colorectal cancer and ECOG 0–1 receive oral PF-08032562, an investigational KAT6A/KAT6B/KAT7 inhibitor, alone or with fulvestrant (breast cancer), cetuximab (colorectal cancer), or FOLFOX plus bevacizumab (colorectal cancer). Prior-treatment requirements vary by cohort.

ClinicalTrials.gov ID: NCT07318805